Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 522877 | ISIN: DE0005228779 | Ticker-Symbol: OBS
Tradegate
26.04.24
21:58 Uhr
6,000 Euro
0,000
0,00 %
Branche
Software
Aktienmarkt
General Standard
1-Jahres-Chart
ORBIS SE Chart 1 Jahr
5-Tage-Chart
ORBIS SE 5-Tage-Chart
RealtimeGeldBriefZeit
5,9006,05028.04.
5,9006,05026.04.
ACCESSWIRE
649 Leser
Artikel bewerten:
(2)

QUAD A Re-Accredits Orbis: Recognizing Excellence in Global Eye Health

HIGHLAND PARK, IL / ACCESSWIRE / October 13, 2023 / QUAD A, the distinguished accrediting body dedicated to ensuring the highest standards in global healthcare, proudly announces the re-accreditation of the Orbis Flying Eye Hospital. This re-accreditation exemplifies QUAD A's commitment to upholding exceptional patient care, safety, and excellence within the healthcare industry.

QUAD A's rigorous evaluation process reaffirms Orbis's position as a leader in the global eye health sector. By achieving QUAD A re-accreditation, Orbis continues to demonstrate its commitment to providing outstanding eye care services to communities worldwide.

At the core of Orbis's innovative approach lies its flying surgery center-a symbol of innovation and expertise. As the re-accreditation celebration commences in Zambia, this remarkable facility transcends geographical confines. The flying surgery center takes flight once more, embarking on a mission to deliver essential medical care, training, and capacity-building initiatives to communities spanning continents. Its global impact knows no bounds-bringing renewed hope and life-changing interventions to diverse regions.

"At QUAD A, our mission is to recognize and promote excellence in healthcare organizations globally. Orbis's re-accreditation underscores their commitment to delivering quality eye care services and their impact in the fight against avoidable blindness," Tom Terranova, JD MA MBA, CEO, QUAD A.

Orbis's QUAD A re-accreditation showcases its commitment to excellence and provides a platform for healthcare professionals, medical institutions, and philanthropic organizations to unite in advancing global eye health. By partnering with Orbis, individuals and organizations can contribute significantly to restoring sight and preventing blindness.

QUAD A's recognition of Orbis reinforces the organization's dedication to maintaining the highest industry standards. This re-accreditation attests to Orbis's unwavering commitment to the global fight against avoidable blindness.

About QUAD A:

QUAD A is a leading accrediting body dedicated to ensuring the highest standards in global healthcare. Through rigorous evaluation processes, QUAD A recognizes and promotes excellence in healthcare organizations worldwide. By accrediting organizations like Orbis, QUAD A plays a crucial role in advancing patient care, safety, and quality within the healthcare industry.

For more information about QUAD A, please visit: www.quada.org

XXXX

For media inquiries or to schedule an interview, please contact:

Kristina Charles, MS
Director of Public Relations, brandRUSSO
kristina@brandrusso.com

SOURCE: QUAD A

View source version on accesswire.com:
https://www.accesswire.com/792986/quad-a-re-accredits-orbis-recognizing-excellence-in-global-eye-health

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 ACCESSWIRE
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.